ORKA
HEALTHCAREARCA biopharma Inc
$69.79+0.84 (+1.22%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ORKA Today?
No stock-specific AI insight has been generated for ORKA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.91$91.00
$69.79
Fundamentals
Market Cap$4.2B
P/E Ratio—
EPS$-1.85
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin—
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding59.9M
ORKA News
21 articles- Halozyme and Oruka sign agreement for Hypercon technologyPharmaceutical-technology·May 7, 2026
- Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ TechnologyYahoo Finance·May 6, 2026
- Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001Yahoo Finance·Apr 30, 2026
- Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public OfferingGlobeNewswire Inc.·Apr 28, 2026
- Oruka Therapeutics Touts “Category-Winning” ORKA-001 Data, Targets Once-Yearly Psoriasis DosingMarketbeat·Apr 28, 2026
- Oruka Therapeutics (ORKA) Hits Record High on Stellar Clinical Trial ResultYahoo Finance·Apr 28, 2026
- Oruka Therapeutics Announces Proposed $500 Million Underwritten Public OfferingBenzinga·Apr 27, 2026
- How A Small Biotech Name Just Rattled AbbVie's $18 Billion FranchiseYahoo Finance·Apr 27, 2026
- Oruka Therapeutics psoriasis drug clears skin in 64% of patientsQz·Apr 27, 2026
- Oruka Therapeutics Shares Jump on Strong Psoriasis Trial ResultsAdvfn·Apr 27, 2026
- Oruka surges as long-acting psoriasis drug shows early promiseBiopharmadive·Apr 27, 2026
- Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque PsoriasisYahoo Finance·Apr 27, 2026
- Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026Yahoo Finance·Apr 26, 2026
- Oruka Insider Sells $463K in Stock as Shares Skyrocket 650%, but Here's What Matters for InvestorsMotley Fool·Apr 21, 2026
- Oruka Therapeutics price target raised to $85 from $45 at WedbushYahoo Finance·Apr 15, 2026
- The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightGlobeNewswire Inc.·Apr 14, 2026
- This Startup’s Psoriasis Drug Studies Have Lifted Its StockYahoo Finance·Apr 10, 2026
- Up Nearly 840% in a Year, Does This ‘Strong Buy’ Stock Have More Room to Run?Barchart·Apr 8, 2026
- Does Oruka’s Widening Loss and ESOP Shelf Registration Change The Bull Case For Oruka Therapeutics (ORKA)?Yahoo Finance·Mar 25, 2026
- Does Oruka Therapeutics, Inc. (ORKA) Have the Potential to Rally 41.51% as Wall Street Analysts Expect?Yahoo Finance·Mar 17, 2026
- Company News for Mar 16, 2026Yahoo Finance·Mar 16, 2026
All 21 articles loaded
Price Data
Open$69.62
Previous Close$68.95
Day High$71.02
Day Low$68.60
52 Week High$91.00
52 Week Low$8.91
52-Week Range
$8.91$91.00
$69.79
Fundamentals
Market Cap$4.2B
P/E Ratio—
EPS$-1.85
Dividend Yield—
Dividend / Share—
ROE-0.2%
Profit Margin—
Debt / Equity—
Trading
Volume1.9M
Avg Volume (10D)—
Shares Outstanding59.9M
About ARCA biopharma Inc
Oruka Therapeutics, Inc. is a biotechnology company.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—